latest news releases from the newsroom
Dyer & Berens LLP
Dyer & Berens LLP Files Class Action Lawsuit On Behalf of Investors in PharmaNet Development Group, Inc. -- PDGI
DENVER, Nov. 24, 2008 (GLOBE NEWSWIRE) -- Dyer & Berens LLP (www.DyerBerens.com) today announced that it has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of investors of PharmaNet Development Group, Inc. ("PharmaNet" or the "Company") (Nasdaq:PDGI) who purchased common stock between November 1, 2007 and April 30, 2008, inclusive (the "Class Period"). The complaint charges PharmaNet and certain of its officers and directors with violations of the Securities Exchange Act of 1934.
Hampton Roads Bankshares, Inc.
Bank of Hampton Roads Announces 'Crush Hunger' Food Drive
NORFOLK, Va., Nov. 24, 2008 (GLOBE NEWSWIRE) -- Bank of Hampton Roads, a subsidiary of Hampton Roads Bankshares (Nasdaq:HMPR), is very proud to announce that from December 1st through 18th, it will hold a CRUSH HUNGER Food Drive to benefit the Foodbank of Southeastern Virginia. Donations of non-perishable food items donations will be accepted at all eighteen Bank of Hampton Roads locations.
Harsco Enters New Relationship With China's Largest Stainless Steel Producer
HARRISBURG, Pa., Nov. 24, 2008 (GLOBE NEWSWIRE) -- Worldwide industrial services company Harsco Corporation (NYSE:HSC) announced today it has signed a Letter of Intent with China's largest stainless steel producer to develop a new working relationship for the treatment and utilization of stainless and carbon steel slag in China.
Dyer & Berens LLP
Dyer & Berens LLP Announces Its Investigation Concerning Losses Suffered by Certain KV Pharmaceutical Company Investors
DENVER, Nov. 24, 2008 (GLOBE NEWSWIRE) -- The law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that it has initiated an investigation concerning losses suffered by investors who purchased the common stock of KV Pharmaceutical Company (NYSE:KV-A) (NYSE:KV-B) between February 15, 2008 and November 12, 2008. The investigation concerns whether the company may have made materially false and misleading statements about its compliance with federal regulations concerning the manufacture and marketing of certain generic drug products as well as its financial prospects.